326 related articles for article (PubMed ID: 29916993)
1. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
[TBL] [Abstract][Full Text] [Related]
3. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Chrysant SG
J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
[TBL] [Abstract][Full Text] [Related]
5. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
6. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Kario K
Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.
Polina I; Domondon M; Fox R; Sudarikova AV; Troncoso M; Vasileva VY; Kashyrina Y; Gooz MB; Schibalski RS; DeLeon-Pennell KY; Fitzgibbon WR; Ilatovskaya DV
Am J Physiol Renal Physiol; 2020 Jul; 319(1):F63-F75. PubMed ID: 32463726
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
Sible AM; Nawarskas JJ; Alajajian D; Anderson JR
Cardiol Rev; 2016; 24(1):41-7. PubMed ID: 26466333
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.
Roksnoer LC; van Veghel R; Clahsen-van Groningen MC; de Vries R; Garrelds IM; Bhaggoe UM; van Gool JM; Friesema EC; Leijten FP; Hoorn EJ; Danser AH; Batenburg WW
Clin Sci (Lond); 2016 Jul; 130(14):1209-20. PubMed ID: 27129187
[TBL] [Abstract][Full Text] [Related]
12. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J
Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Sironi L; Gelosa P; Guerrini U; Banfi C; Crippa V; Brioschi M; Gianazza E; Nobili E; Gianella A; de Gasparo M; Tremoli E
J Pharmacol Exp Ther; 2004 Dec; 311(3):989-95. PubMed ID: 15302895
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
15. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
16. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W
J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595
[TBL] [Abstract][Full Text] [Related]
18. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]